September 21, 2020 -- PharmAbcine and Samsung Biologics have entered into a new strategic partnership for the development and manufacturing of PMC-403, a next-generation antibody therapeutic candidate to treat neovascular disorders.
Samsung will provide contract development organization services including cell line development, process development, current good manufacturing practice clinical manufacturing, and investigational new drug filing support.
PMC-403 is a novel agonistic antibody that binds to the human Tie2 receptor. PharmAbcine is developing the therapy to treat nonocular and ocular pathological vessel-related diseases. The company expects PMC-403 to enter a global ophthalmological clinical trial in 2022.
This is PharmAbcine's first significant undertaking of its angiogenesis assets outside of oncology applications.